General Catalyst launches EU AI Champions Initiative
The initiative brings together more than 60 companies in Europe and aims to “unlock Europe’s full potential in AI.”
Related Articles
The biggest science breakthroughs in 2024
From nitrogen-fixing organelles to a new form of magnetism, 2024 was full of scientific advances
Executives forecast AI’s place in healthcare in 2025, part one
AI will transform healthcare with advances in multimodal technology, diagnostic imaging and automation, but its success depends on trust and seamless integration into workflows.
Amyloid-associated hyperconnectivity drives tau spread across connected brain regions in Alzheimer’s disease
Aβ induces neuronal hyperconnectivity, which promotes tau spreading from temporal lobe epicenters to connected brain regions in Alzheimer’s disease.
Fully-Automated CAR-T Bioprocessing Platform Aids Scalability
Trenchant partnered with Autolomous, integrating its digital solution into its CGT manufacturing platform, for faster production and lower costs.
Indonesia’s new capital could become a hot spot for infectious diseases
Scientists worry about potential surge of a rare malaria parasite and a host of mosquito-borne viruses
Learning the language of life with AI
In 2021, a year before ChatGPT took the world by storm amid the excitement about generative artificial intelligence (AI), AlphaFold 2 cracked the 50-year-old protein-folding…
Trump orders cause chaos at science agencies
Wild week of canceled meetings, program changes, and data purges creates high anxiety
Chatbot Software Begins to Face Fundamental Limitations | Quanta Magazine
Recent results show that large language models struggle with compositional tasks, suggesting a hard limit to their abilities.
StockWatch: Illumina Tumbles on Q4 Results, China Retaliation
For all of last year, Illumina’s net loss grew 5% from $1.161 billion to $1.223 billion, on revenue that fell 3% from $4.505 billion to…
Recoding E. coli Genome for Programmable Synthetic Proteins
Nonstandard amino acids imbue proteins with multiple new properties such as programmable biologics with reduced immunogenicity.